Linsitinib (OSI-906)

Catalog No.S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 33 Publications

6 Customer Reviews

  • (e) c-peptide from these mice 240 min after respective treatments.

    Nature, 2018, 560(7719):499-503. Linsitinib (OSI-906) purchased from Selleck.

    Inhibition of IGF receptor by the IGFR inhibitor linsitinib reduced ERK1/2 signaling activation particularly in U87MG RG7388 resistant cells.

    Clin Cancer Res, 2018, doi:10.1158/1078-0432.CCR-18-1580. Linsitinib (OSI-906) purchased from Selleck.

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk NEDnXYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HyUGlEPTB;MD6wNlgxPiEQvF2= M{HVdXNCVkeHUh?=
KS-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPvdW9KSzVyPUCuNFM5OzVizszN MVXTRW5ITVJ?
TE-11 NVzHWY9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS4PYlKSzVyPUCuNFc5OjJizszN MWDTRW5ITVJ?
EW-1 NFH3dIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD6W5ZEUUN3ME2wMlA5PTh3IN88US=> NUXZcYVzW0GQR1XS
HMV-II MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXiNXl6UUN3ME2wMlA5QDR4IN88US=> NXnNboNRW0GQR1XS
COLO-205 NFjSXYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK5R3dKSzVyPUCuNVA1PTRizszN M2nheXNCVkeHUh?=
ES1 NVqzfmZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXSfpVPUUN3ME2wMlExPjl4IN88US=> MnvWV2FPT0WU
GDM-1 NGPBR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr0TWM2OD1yLkGzOlczKM7:TR?= NInmfWFUSU6JRWK=
ML-2 M3PWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMUW4PVYh|ryP NFjyXWVUSU6JRWK=
Saos-2 NXTDZ5NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:xVGlEPTB;MD6xOlUzPiEQvF2= NETGNpdUSU6JRWK=
NCI-H1355 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LofGlEPTB;MD6xPFE{PSEQvF2= MVzTRW5ITVJ?
G-401 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[5VHQ1UUN3ME2wMlE5OjNizszN M1v2RnNCVkeHUh?=
EW-16 M3\HXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHZOFRGUUN3ME2wMlE5Pzd5IN88US=> NIj3d4tUSU6JRWK=
EW-7 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1e1SmlEPTB;MD6xPFg5OSEQvF2= MYrTRW5ITVJ?
NCI-H727 M2jSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwMUm3PVQh|ryP MVrTRW5ITVJ?
LCLC-97TM1 NILaPWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnMTWM2OD1yLkKwPVU2KM7:TR?= M{nLXHNCVkeHUh?=
NCI-H650 NEn0V4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLSboFKSzVyPUCuNlE{QDRizszN NXKwWnVpW0GQR1XS
NCI-H2122 NFzSdYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;5TZJKSzVyPUCuNlMzQTlizszN MVvTRW5ITVJ?
SK-N-DZ MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[1TWM2OD1yLkKzOlk5KM7:TR?= MV\TRW5ITVJ?
HT-29 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi3TIVSUUN3ME2wMlI1OjR6IN88US=> Ml7CV2FPT0WU
LB771-HNC MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLsTWM2OD1yLkK1PVE2KM7:TR?= NH:3flJUSU6JRWK=
HT-144 M1ztZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\iRmlEPTB;MD6yOlE6OSEQvF2= NXjxWJN3W0GQR1XS
LAN-6 NYfSeWJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwMk[zOFgh|ryP M3z5ZXNCVkeHUh?=
EW-18 NF:4TmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDsOGFoUUN3ME2wMlI4ODBzIN88US=> NYf6eGpQW0GQR1XS
LS-1034 MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnl[m8zUUN3ME2wMlI4OTN{IN88US=> M{P1UXNCVkeHUh?=
EW-11 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMki0N|Ih|ryP NIqz[ZdUSU6JRWK=
SNU-C1 M1TLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL2e|JKSzVyPUCuNlk{OTNizszN NV3STJVWW0GQR1XS
RS4-11 NYfhVJd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwM{O3OVgh|ryP MmLIV2FPT0WU
ES4 NVz5RpB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoOwTWM2OD1yLkSxNFM5KM7:TR?= NUnLepRFW0GQR1XS
COLO-320-HSR M3vHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwNEGzOlgh|ryP MlHFV2FPT0WU
NB10 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H5SWlEPTB;MD60OVQ{PyEQvF2= NYLVdXB{W0GQR1XS
BFTC-905 NYDEV4JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHtT4pKSzVyPUCuOFY4PThizszN MV;TRW5ITVJ?
A375 NH7mUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7NOI5XUUN3ME2wMlQ4PjF5IN88US=> MmPvV2FPT0WU
SJRH30 M2DWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHhTWM2OD1yLkWwPFIzKM7:TR?= NE\X[5JUSU6JRWK=
NOS-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHHTWM2OD1yLkWyNlY4KM7:TR?= NG\Pb3NUSU6JRWK=
SIG-M5 MnHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXVSmNKSzVyPUCuOVM2PTdizszN NX7uPXFPW0GQR1XS
DOK MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\FTWM2OD1yLkW1OkDPxE1? NGHsVmxUSU6JRWK=
NB69 MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TJPGlEPTB;MD61PFI2PyEQvF2= M{X2PXNCVkeHUh?=
SK-NEP-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;vTWlEPTB;MD62NFI{PiEQvF2= NEnpOIJUSU6JRWK=
SK-MM-2 NWj0fI1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP0UYtSUUN3ME2wMlY2PDlzIN88US=> NVTTXZdPW0GQR1XS
NCI-H358 MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnhS|B3UUN3ME2wMlY4ODh{IN88US=> NX23d|BlW0GQR1XS
RH-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHtTWM2OD1yLke0PFU6KM7:TR?= NVPjN3k3W0GQR1XS
NH-12 M3:wV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnhTndXUUN3ME2wMlc3ODR4IN88US=> NV3MUJZTW0GQR1XS
TE-12 M{LvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PoW2lEPTB;MD63OlQ5PiEQvF2= NXny[WlDW0GQR1XS
COLO-668 M3n0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3S[XpKSzVyPUCuPFQ3PjZizszN MknaV2FPT0WU
PANC-08-13 NELlV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwOE[zO|ch|ryP NHrMOpRUSU6JRWK=
HCC2998 M3\SXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTmTXRKSzVyPUCuPFgzPjNizszN NF\SfHNUSU6JRWK=
ABC-1 MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjXTWM2OD1yLkmwN|UzKM7:TR?= M1v4[HNCVkeHUh?=
ES6 NGHNZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFKyS4VKSzVyPUCuPVExPjZizszN MWTTRW5ITVJ?
SNU-387 M1LGR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXzTWM2OD1yLkm5N|k{KM7:TR?= NWfhNW1qW0GQR1XS
CMK MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL6TWM2OD1yLkm5PVI6KM7:TR?= M1j0eXNCVkeHUh?=
SJSA-1 M4T3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLmTWM2OD1zLkCzOlU{KM7:TR?= NVnrOWNSW0GQR1XS
SIMA MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmf0TWM2OD1zLkC2PFI2KM7:TR?= NUL3bXM1W0GQR1XS
ES3 NV7GNmFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLuTWM2OD1zLkGyNlk4KM7:TR?= M4HTdXNCVkeHUh?=
IGROV-1 M2rmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFwMUW0OFQh|ryP M2j0enNCVkeHUh?=
MEL-JUSO MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\aRWNmUUN3ME2xMlE2PzV7IN88US=> M4Dxe3NCVkeHUh?=
T84 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXtTWM2OD1zLkKwPVE1KM7:TR?= NFLLZZdUSU6JRWK=
CAL-85-1 M1vVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTFwMkOxN|gh|ryP MljRV2FPT0WU
RD NHjEeXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1j1e2lEPTB;MT6yOlQ2PSEQvF2= NFn3eVdUSU6JRWK=
TE-8 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrJfJJNUUN3ME2xMlMyPDZ{IN88US=> NGnPVVBUSU6JRWK=
L-363 M{DBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXhTWM2OD1zLkO0NlA5KM7:TR?= NX3WPFUxW0GQR1XS
EKVX M2LUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XrU2lEPTB;MT6zOFU3QCEQvF2= NEnoPGVUSU6JRWK=
SK-MEL-3 NGnPbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\QRmlEPTB;MT60PFU2PiEQvF2= M3fRPXNCVkeHUh?=
TGBC24TKB MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDOTWM2OD1zLkWwNVk{KM7:TR?= M4KyXHNCVkeHUh?=
NCI-H1770 M3;r[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3juV2lEPTB;MT61NVEyOyEQvF2= NEn0To9USU6JRWK=
HuH-7 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFwNkCwPVgh|ryP NFfMeYdUSU6JRWK=
HL-60 NHnBbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnj6TWM2OD1zLk[2PVI5KM7:TR?= M{L0cXNCVkeHUh?=
TE-1 NFK0e|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrVTnJKSzVyPUGuO|A6PDVizszN NEmydWlUSU6JRWK=
LC-2-ad M3nZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTCblBOUUN3ME2xMlc{QDh5IN88US=> MoHlV2FPT0WU
LB647-SCLC M2rJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[wbYhKSzVyPUGuO|Y2QDNizszN NUT6eYVGW0GQR1XS
NCI-H2171 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFwN{e3NVYh|ryP M1n4[nNCVkeHUh?=
SK-PN-DW MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInLTHhKSzVyPUGuPVEzQThizszN M33aXHNCVkeHUh?=
MC-IXC NGH3WJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTFwOUi5PEDPxE1? MlnpV2FPT0WU
LS-513 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;5NGlEPTB;Mj6wOVMxPSEQvF2= M1\LSXNCVkeHUh?=
EW-3 NYq2eIFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HwO2lEPTB;Mj6wPVg1PCEQvF2= M3vRVnNCVkeHUh?=
OPM-2 M2HONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzrUIpkUUN3ME2yMlExOiEQvF2= MnHlV2FPT0WU
LP-1 NETZ[HVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJwMkW4NFch|ryP M2fxVXNCVkeHUh?=
LU-134-A NFu5VJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrETWM2OD1{LkK3O{DPxE1? NVOwSVh6W0GQR1XS
CP66-MEL NEe2NVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJwMkmwNVQh|ryP MWfTRW5ITVJ?
HCC1143 M2\He2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzISIRKSzVyPUKuOFU{PjhizszN M2X1WHNCVkeHUh?=
LOXIMVI MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{juU2lEPTB;Mj62NFIyKM7:TR?= M4\PbnNCVkeHUh?=
TE-10 M4\MTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfETWM2OD1{LkewPFM5KM7:TR?= NF3y[mdUSU6JRWK=
NCI-H1882 NYnrbZVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTMZpBKSzVyPUKuO|UzOjdizszN Mnu1V2FPT0WU
CHP-126 M1LjcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHFW|FuUUN3ME2yMlc3OzF5IN88US=> M4r0T3NCVkeHUh?=
NCI-H1623 NYfJToRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS3SZliUUN3ME2yMlkzODJ2IN88US=> NV3XNXpPW0GQR1XS
GB-1 MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrTTWM2OD1{LkmzOFA1KM7:TR?= MYrTRW5ITVJ?
RCC10RGB NGD0eYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJwOUWyPFEh|ryP NVTIS4t2W0GQR1XS
NCI-H2141 M3:1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT2TWM2OD1{Lkm2PFk3KM7:TR?= MUXTRW5ITVJ?
GI-ME-N NFTF[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfjU5lKSzVyPUOuNFA2PjVizszN MY\TRW5ITVJ?
NCI-H526 M2Kyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPleVdKSzVyPUOuNFQxQDVizszN NXTHbmRmW0GQR1XS
NCI-H747 M2fNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\ZTWM2OD1|LkC0PVkzKM7:TR?= Ml;GV2FPT0WU
SNU-423 NEn5SVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2WxU2lEPTB;Mz6yNFMyOyEQvF2= M3;CPXNCVkeHUh?=
A427 NF3uXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvrTWM2OD1|LkK1Olk6KM7:TR?= NVzhSopXW0GQR1XS
CAL-12T MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTNwNEC3NVMh|ryP MkTvV2FPT0WU
LU-99A NW\BUVhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTNwNEexNFUh|ryP M33PNXNCVkeHUh?=
MS-1 NGLR[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NECwT4dKSzVyPUOuOVM1OjlizszN NXv1T2xYW0GQR1XS
SK-LU-1 M{GxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DQcWlEPTB;Mz63OlI6PSEQvF2= NFTWOJFUSU6JRWK=
SW837 NGq1R|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfITWM2OD1|Lke2N|M{KM7:TR?= M1XUTXNCVkeHUh?=
ES8 NHr1[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33HVGlEPTB;Mz64N|g4PyEQvF2= NYLLfFU3W0GQR1XS
MZ2-MEL M3;YXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjQS3hKSzVyPUOuPVIxQDZizszN NUC3SXdQW0GQR1XS
TGW NWTWdZhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnTVIJXUUN3ME20MlAyOzFzIN88US=> NIrBcmFUSU6JRWK=
GP5d MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTRwMEWzOlIh|ryP MV7TRW5ITVJ?
BB49-HNC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUWzOXNXUUN3ME20MlE2OjF|IN88US=> NIP3TWdUSU6JRWK=
NB13 NFW0dVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPVTWM2OD12LkK2PFg4KM7:TR?= NEjiNGdUSU6JRWK=
NTERA-S-cl-D1 NX2zeod3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXyTWM2OD12LkK4OlE2KM7:TR?= NETqXGJUSU6JRWK=
NCI-H1648 NIqx[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zpc2lEPTB;ND6yPVgyQSEQvF2= MmnBV2FPT0WU
LCLC-103H NXnYNZBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTRwM{KxPVUh|ryP NU[w[HdEW0GQR1XS
LS-411N NYG1R4E{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1viWWlEPTB;ND60OFg5PSEQvF2= NEnI[5dUSU6JRWK=
NCI-H1092 MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTRwNEW2PFch|ryP NEPqU4tUSU6JRWK=
PANC-10-05 NILicXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTRwNkm4OEDPxE1? MoDuV2FPT0WU
DK-MG Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfw[29KSzVyPUSuPFA6OzNizszN MVHTRW5ITVJ?
OVCAR-5 NVzi[lJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3W[29bUUN3ME20MlgyOjJ4IN88US=> MluzV2FPT0WU
CAL-39 M1HJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HCT2lEPTB;ND64O|Y4KM7:TR?= NUftOndIW0GQR1XS
TE-441-T NGX2ZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDoTWM2OD12LkmwOVM4KM7:TR?= M2XiUXNCVkeHUh?=
MOLT-16 MonjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPwTWM2OD12Lkm1NlU{KM7:TR?= NE[0UYhUSU6JRWK=
MCF7 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LKT2lEPTB;NT6xOFUyPyEQvF2= NGLNPHhUSU6JRWK=
CAPAN-1 NUjCOFNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHUb2NKSzVyPUWuNlU4ODdizszN MWPTRW5ITVJ?
PSN1 NF76bJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXnbGVIUUN3ME21MlI4OjN3IN88US=> NF\qemZUSU6JRWK=
NCI-H292 MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvofm5KSzVyPUWuN|AxPDRizszN MVzTRW5ITVJ?
CPC-N NXG0c|V{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;rS29KSzVyPUWuN|k1OTlizszN NYjYdHBLW0GQR1XS
DoTc2-4510 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTVwNEWzO|Eh|ryP NFjjcmlUSU6JRWK=
LB1047-RCC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHZblNKSzVyPUWuOVU6OzNizszN MUnTRW5ITVJ?
MHH-ES-1 NGCwbFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTVwNUm5NFch|ryP M2f5cnNCVkeHUh?=
NMC-G1 NIXSdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HWWmlEPTB;NT63NFIzPyEQvF2= NXLlN3R2W0GQR1XS
SW1710 NI[5dXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHkRW5KSzVyPUWuO|Q4PTFizszN NX3VeHNHW0GQR1XS
YAPC M1mwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PZW2lEPTB;NT63OlIxOSEQvF2= M2\wZnNCVkeHUh?=
22RV1 MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvuTWM2OD13LkiwNFE6KM7:TR?= NF\zWFhUSU6JRWK=
COLO-679 NX\McmdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zTVGlEPTB;NT64PFk1QCEQvF2= NFPYZohUSU6JRWK=
TCCSUP MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX3V3V4UUN3ME21Mlk{OjV7IN88US=> NXXqW3NiW0GQR1XS
C2BBe1 NXKyOFZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:5V4VyUUN3ME21Mlk{QTdizszN MnH0V2FPT0WU
TE-15 MkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTZwME[2NFUh|ryP NF\BfHJUSU6JRWK=
SCLC-21H M3ez[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjHTWM2OD14LkGwPFQ{KM7:TR?= MlfnV2FPT0WU
EoL-1-cell M1T1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLCTWM2OD14LkG2OVY{KM7:TR?= NYfSc4dIW0GQR1XS
NKM-1 M3j3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoeyTWM2OD14LkG2O|Eh|ryP NFXsbXBUSU6JRWK=
NCI-H1304 NYXU[opKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTuTWM2OD14LkK3OFI5KM7:TR?= MV;TRW5ITVJ?
NB6 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFviOlRKSzVyPU[uNlk3OjJizszN NXe5fHNVW0GQR1XS
NALM-6 M3TkOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHWzVplKSzVyPU[uN|MzOyEQvF2= MY\TRW5ITVJ?
NCI-H522 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFW2d3pKSzVyPU[uN|M{ODZizszN NFzS[nlUSU6JRWK=
MV-4-11 NXTxcFFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvQWZk1UUN3ME22MlM4ODd7IN88US=> MY\TRW5ITVJ?
LB2241-RCC M1LUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPkTmRKSzVyPU[uN|g3PjdizszN M3j6WHNCVkeHUh?=
NCI-H1417 M4jZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3BTWM2OD14LkSwPFQ4KM7:TR?= NGLDVm5USU6JRWK=
HT-1197 M3W2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPlUFFKSzVyPU[uOVcyOjJizszN Mn3QV2FPT0WU
P30-OHK NVz6VINqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTZwNkK3O{DPxE1? M2DsN3NCVkeHUh?=
ALL-PO M3TacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrlTWM2OD14LkexPVE3KM7:TR?= NF2zXoVUSU6JRWK=
OVCAR-4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHSS4hKSzVyPU[uO|U1ODVizszN MXnTRW5ITVJ?
HCC2157 MlL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjEOGJKSzVyPU[uO|c1PzVizszN M2DOOXNCVkeHUh?=
NCI-H838 Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHSyU21KSzVyPU[uPVY1QSEQvF2= MXPTRW5ITVJ?
NCI-H1299 M2XHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTZwOUewPUDPxE1? NHz3N|JUSU6JRWK=
SW954 MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvtTWM2OD15LkKwNFY5KM7:TR?= M13HeXNCVkeHUh?=
NCI-H441 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDqc4tKSzVyPUeuN|QxPjVizszN NVrXWIJQW0GQR1XS
SK-MEL-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fNWWlEPTB;Nz60PFM4OyEQvF2= Mn\DV2FPT0WU
KARPAS-45 NUT5[pNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXi[XJjUUN3ME23MlY2QTJ7IN88US=> MUXTRW5ITVJ?
CAL-54 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTdwOEK5O|ch|ryP MUnTRW5ITVJ?
KYSE-180 NWfCZ3JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTdwOEi5OFEh|ryP MVHTRW5ITVJ?
NCI-H187 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rtdGlEPTB;Nz65OVk1PyEQvF2= MWHTRW5ITVJ?
RT-112 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfiTWM2OD16LkC5Olc4KM7:TR?= MmTSV2FPT0WU
NCI-H1437 NH\kN2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRThwMEm3PVUh|ryP M3TiWHNCVkeHUh?=
SNU-449 NFr3VppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIracXlKSzVyPUiuNlgzPzJizszN Ml:1V2FPT0WU
HCC1187 NVXZZpVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LmXGlEPTB;OD6yPVM6OSEQvF2= MkPYV2FPT0WU
NCI-H2030 M3vCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrQTWM2OD16LkO3O|E1KM7:TR?= NV\GXG8yW0GQR1XS
HuO-3N1 Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFntb21KSzVyPUiuN|c5PDRizszN MmGyV2FPT0WU
COLO-792 M3HNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRThwNEG1Nlch|ryP M4jGc3NCVkeHUh?=
MIA-PaCa-2 NHTUT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRThwOEW1NFgh|ryP NHLLZpFUSU6JRWK=
SK-N-FI NVz6VYZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTlwMESyOUDPxE1? MmfnV2FPT0WU
MMAC-SF NIjOV4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D0UmlEPTB;OT6wPVc2OSEQvF2= MY\TRW5ITVJ?
NCI-H28 M3;3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;zO|ZtUUN3ME25MlExPDZ7IN88US=> NU\QfYtEW0GQR1XS
ETK-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLqcJhKSzVyPUmuNlk6PzRizszN MoixV2FPT0WU
NCI-H1993 NYPrOpY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2WyUGlEPTB;OT60OFI3OSEQvF2= NFzNc2pUSU6JRWK=
no-11 M2exRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rsVmlEPTB;OT60O|EzKM7:TR?= NInQZo9USU6JRWK=
ChaGo-K-1 NFnnW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTlwNUG1PFMh|ryP M3zTVHNCVkeHUh?=
NCCIT NYDobWlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4exT2lEPTB;OT61N|E3QSEQvF2= NFHxN4tUSU6JRWK=
SAS MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDSTWM2OD1zMD6yOFgh|ryP MXXTRW5ITVJ?
A673 NF3lU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnudpZKSzVyPUGwMlM4ODRizszN MX;TRW5ITVJ?
NCI-H1522 NF\FNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD2XGQ2UUN3ME2xNE4{PzB5IN88US=> NHPjfolUSU6JRWK=
NCI-H810 M{P4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jyRWlEPTB;MUCuN|kxPyEQvF2= NYnTZ2JzW0GQR1XS
IST-MES1 NWDoeJo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnyxTWM2OD1zMD60OVY1KM7:TR?= MlPLV2FPT0WU
GR-ST MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUj3ZWo{UUN3ME2xNE42ODJ2IN88US=> MVXTRW5ITVJ?
SUP-T1 NIm4TZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHYTWM2OD1zMD63N|E4KM7:TR?= MVHTRW5ITVJ?
NB5 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGm4UXpKSzVyPUGwMlkxOjJizszN NH\mbYhUSU6JRWK=
MZ1-PC MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTFyLkm1O|Eh|ryP NGSzR|ZUSU6JRWK=
SK-CO-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjhfXNVUUN3ME2xNE46QTNzIN88US=> NYrX[HRKW0GQR1XS
Capan-2 M1rITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDDTWM2OD1zMT6zNVk5KM7:TR?= MXnTRW5ITVJ?
697 MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFzLk[3OVch|ryP NX[zTI1mW0GQR1XS
REH Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;GPYRKSzVyPUGxMlc1PTFizszN NFrBS2VUSU6JRWK=
GI-1 M3HoUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL4TWM2OD1zMT64OlE2KM7:TR?= MkL3V2FPT0WU
BB65-RCC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLiTWM2OD1zMj6wPVE3KM7:TR?= NWPFb2RMW0GQR1XS
NCI-H1651 MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[xbIRKUUN3ME2xNk4zPDd6IN88US=> NH64[o9USU6JRWK=
NCI-H1618 NVH0TWJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nNUmlEPTB;MUKuN|k4PiEQvF2= NF7HTYVUSU6JRWK=
NCI-H2081 M2\zWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;HNpNKSzVyPUGyMlYyPDFizszN MUXTRW5ITVJ?
GCIY MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\0UGlEPTB;MUKuO|IyOyEQvF2= NUnaVXBEW0GQR1XS
NY NEHpUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f5RmlEPTB;MUOuNFY1OyEQvF2= MnXWV2FPT0WU
PANC-03-27 NUmwN5NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTF|LkC4NFch|ryP M{XSOXNCVkeHUh?=
BHY NVjnTJo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrLNXZKSzVyPUGzMlIyOjFizszN NGXqbmlUSU6JRWK=
SK-OV-3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PaSWlEPTB;MUOuN|c3OyEQvF2= MnfFV2FPT0WU
5637 MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\aTZp1UUN3ME2xN{44PzV7IN88US=> M2LobXNCVkeHUh?=
LC-1F NE\YTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPye2FrUUN3ME2xOE4xOzV4IN88US=> MWHTRW5ITVJ?
SNB75 NYntZW05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zCcWlEPTB;MUSuNFM5OyEQvF2= NFfXNnJUSU6JRWK=
CHP-212 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrRVW56UUN3ME2xOE4xPDZ2IN88US=> NEmzNGlUSU6JRWK=
HT-1376 Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnSTWM2OD1zND6xNVI3KM7:TR?= MorWV2FPT0WU
MONO-MAC-6 MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;KZndoUUN3ME2xOE4yPTB{IN88US=> MnG0V2FPT0WU
CA46 MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nK[2lEPTB;MUSuNVgzPyEQvF2= NXy1[m1DW0GQR1XS
SCC-15 M1f5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV32fHo4UUN3ME2xOE42PTh|IN88US=> NWLmfZRrW0GQR1XS
ATN-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrCb3NXUUN3ME2xOE43PjJ5IN88US=> M2nQVHNCVkeHUh?=
NCI-H2405 M3\uXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf3V49KSzVyPUG0MlgyPTdizszN MlPFV2FPT0WU
NCI-H716 M12xOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTEc5VDUUN3ME2xOE45PDl|IN88US=> NEfvWJhUSU6JRWK=
SW620 NFvMZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fxUWlEPTB;MUSuPVAyPCEQvF2= M330V3NCVkeHUh?=
NCI-H226 NXvwR4FLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjMTWM2OD1zND65NFg2KM7:TR?= MWLTRW5ITVJ?
SW962 NGLOOXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD0TWM2OD1zND65OFMzKM7:TR?= M2jZS3NCVkeHUh?=
KYSE-150 M3jZdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfPTWM2OD1zND65OVUh|ryP NWXye45kW0GQR1XS
OCUB-M NV7NXlE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTF2Lkm4PFMh|ryP M4jySnNCVkeHUh?=
ES7 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDnSI9KSzVyPUG1MlA6QDRizszN MVXTRW5ITVJ?
SW1463 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLpUGJKSzVyPUG1MlQzOjNizszN NVH4dJl6W0GQR1XS
CAKI-1 M4[4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTF3LkWzOFYh|ryP NFfhOnVUSU6JRWK=
MKN28 NVH5ZlUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK3TWM2OD1zNT61OFc6KM7:TR?= MVfTRW5ITVJ?
SW13 NEPHSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3WVJVKSzVyPUG1MlYyQCEQvF2= NU\qN5lYW0GQR1XS
A3-KAW NUnPdYc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzjcWZKSzVyPUG1Mlk3QTdizszN MYnTRW5ITVJ?
LU-65 NVrBU|ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlr2TWM2OD1zNT65O|Y5KM7:TR?= M{nLTXNCVkeHUh?=
Calu-1 NG\aeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF62fIlKSzVyPUG2MlA{PjhizszN M{W4UHNCVkeHUh?=
ST486 NHzUXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\Lc4lKSzVyPUG2MlA1OzFizszN M4r0e3NCVkeHUh?=
BB30-HNC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn22TWM2OD1zNj6xNlQ3KM7:TR?= NVfUUI5JW0GQR1XS
EGI-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTN[5NKSzVyPUG2MlQ1PiEQvF2= MkPoV2FPT0WU
SH-4 M2HRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DCfWlEPTB;MU[uOFc{OSEQvF2= Mn\1V2FPT0WU
MN-60 NHzG[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f1SmlEPTB;MUeuNlI6PyEQvF2= MWDTRW5ITVJ?
MPP-89 Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7NTWM2OD1zNz6yOFU6KM7:TR?= MmnrV2FPT0WU
A2780 NFfoXpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{KyXWlEPTB;MUeuOFE{QSEQvF2= NESwXGlUSU6JRWK=
Daoy M4r6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTF5LkS2PVUh|ryP NEjJ[ZFUSU6JRWK=
NCI-H2126 NEf5WIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TVR2lEPTB;MUeuOFc4OSEQvF2= MX\TRW5ITVJ?
NCI-H1563 M1vzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXq[FlKSzVyPUG3MlQ6OTdizszN M{LiT3NCVkeHUh?=
8-MG-BA M1HteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Du[GlEPTB;MUeuOlY1QCEQvF2= MlPaV2FPT0WU
786-0 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULJT5ZVUUN3ME2xO{45OzV|IN88US=> M4XKfXNCVkeHUh?=
AM-38 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PufmlEPTB;MUeuPVMxPiEQvF2= NFTHWoJUSU6JRWK=
COLO-824 M4qxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DvPGlEPTB;MUiuOFQ{PiEQvF2= NYDJOIFRW0GQR1XS
SK-MEL-30 M1PxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrEOXREUUN3ME2xPE42ODh{IN88US=> NYfjd41FW0GQR1XS
CESS M4H0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXiTWM2OD1zOD63OlA6KM7:TR?= NILCemxUSU6JRWK=
BL-70 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfKTZVKSzVyPUG4MlgyPTZizszN MV7TRW5ITVJ?
NCI-H2170 NHHXXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HvWGlEPTB;MUiuPVE4QSEQvF2= NEDFSoZUSU6JRWK=
HT-3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHuOmpKSzVyPUG4Mlk5OyEQvF2= M1nLSnNCVkeHUh?=
BOKU NIf6bFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13r[WlEPTB;MUmuNFM5OSEQvF2= NYG5[XB4W0GQR1XS
HPAF-II NITLe49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInIRW9KSzVyPUG5MlMxOTVizszN MUfTRW5ITVJ?
KGN M1TQb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF7LkS3OlUh|ryP MY\TRW5ITVJ?
MC-CAR NIPCfJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS5TWM2OD1zOT62N|E{KM7:TR?= M3Xqd3NCVkeHUh?=
BHT-101 M1HSe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILBd2ZKSzVyPUG5Mlc4PyEQvF2= NVLCNWxFW0GQR1XS
SW1783 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfEcpdqUUN3ME2xPU44QDB4IN88US=> M4LJbHNCVkeHUh?=
KP-N-YN M13I[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\pTWM2OD1{MD6wNlYzKM7:TR?= NWDFSYloW0GQR1XS
LU-165 MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzWVnZKSzVyPUKwMlU2PzFizszN MlTPV2FPT0WU
GOTO NGrBZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEezeYNKSzVyPUKwMlY1PTFizszN MYjTRW5ITVJ?
EFM-19 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\lTIdGUUN3ME2yNU4xPzF4IN88US=> NFzhXlFUSU6JRWK=
CTV-1 NHu4RXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3u1S2lEPTB;MkGuNVA2PCEQvF2= MlnjV2FPT0WU
HEL Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTJzLkSyNVYh|ryP NVLEe4Z2W0GQR1XS
SNU-C2B MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq5O3NKSzVyPUKxMlQzPiEQvF2= M4DW[XNCVkeHUh?=
ECC4 Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2eycWlEPTB;MkGuO|A4KM7:TR?= MmPRV2FPT0WU
NEC8 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moe1TWM2OD1{MT64N|Y5KM7:TR?= NHLPfWNUSU6JRWK=
KMOE-2 M{X4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLZPY1GUUN3ME2yNU45QTJzIN88US=> M12xdnNCVkeHUh?=
NCI-H524 MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnlb5JTUUN3ME2yNk4xQDB6IN88US=> NGDn[2xUSU6JRWK=
WSU-NHL NXi0Z5FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJ{LkG1O|ch|ryP MkPzV2FPT0WU
SF126 NUH2d4xwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF23N25KSzVyPUKyMlI1PjlizszN MlTYV2FPT0WU
HOP-92 M17pbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJ{LkOxOlch|ryP M1rl[3NCVkeHUh?=
CTB-1 M{j2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W1c2lEPTB;MkKuOFY4PyEQvF2= M{PKdXNCVkeHUh?=
KYSE-270 NEjNSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\oVXFsUUN3ME2yNk46OzV5IN88US=> MofHV2FPT0WU
SK-MEL-24 NFu2PJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvDTWM2OD1{Mz6xPFch|ryP MknYV2FPT0WU
Calu-3 M3[3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfUflJKSzVyPUKzMlIyOjhizszN NV;QU3R1W0GQR1XS
GAMG MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnVZZNKSzVyPUKzMlI{PjdizszN MYXTRW5ITVJ?
SW1573 Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJ|Lke0NVUh|ryP NVPGUG43W0GQR1XS
MHH-NB-11 NHTrV|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7MTWM2OD1{ND6wNVk1KM7:TR?= M2XoRnNCVkeHUh?=
TK10 MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJ2LkWwNVMh|ryP NFXmPJVUSU6JRWK=
LB373-MEL-D MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:2TWM2OD1{ND62NFY1KM7:TR?= M3;TT3NCVkeHUh?=
KALS-1 MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vRT2lEPTB;MkSuO|MzPyEQvF2= NVXUVoNSW0GQR1XS
HUTU-80 MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPoTWM2OD1{NT64NFMzKM7:TR?= MmHhV2FPT0WU
HuP-T3 NV7RSoQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L3e2lEPTB;Mk[uNVY4PCEQvF2= MlXaV2FPT0WU
OE19 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3zTYRKSzVyPUK2MlIyPTNizszN M2G2TXNCVkeHUh?=
J82 M3j2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LKXGlEPTB;Mk[uNlQ4OSEQvF2= M4LqWnNCVkeHUh?=
DU-4475 M2rLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXYVoRKSzVyPUK2MlM5OTlizszN NXvaRoNxW0GQR1XS
DMS-53 NGn6PFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEflOoNKSzVyPUK2MlUyOzhizszN MYPTRW5ITVJ?
COLO-741 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJ4LkizOFQh|ryP MVrTRW5ITVJ?
SW48 M3W0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nQfGlEPTB;Mk[uPFgzKM7:TR?= NWfxRXpGW0GQR1XS
IGR-1 NYS1[|k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7GTWM2OD1{Nj65N|M1KM7:TR?= MUTTRW5ITVJ?
639-V MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7qUGNkUUN3ME2yO{4xOjR3IN88US=> Mlr3V2FPT0WU
LK-2 M3fVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O1OWlEPTB;MkeuOFE1OSEQvF2= NXvVfVF5W0GQR1XS
NCI-H2347 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJ5Lkm2PVkh|ryP Ml;KV2FPT0WU
NCI-H2228 NWTPZ5pbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3yyXmlEPTB;MkiuNFkxPSEQvF2= MX\TRW5ITVJ?
LS-123 M1Phe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFriXI1KSzVyPUK4MlEzPjJizszN M2i5WHNCVkeHUh?=
U031 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33McmlEPTB;MkiuNlUzKM7:TR?= MkLPV2FPT0WU
NCI-H1792 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;DTWM2OD1{OD60O|IyKM7:TR?= MmrPV2FPT0WU
NCI-H2087 M{jkRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLiTWM2OD1{OD63OVUzKM7:TR?= NHzBUmRUSU6JRWK=
NCI-H2342 NGrQb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPYN|J3UUN3ME2yPU42OjB6IN88US=> MV;TRW5ITVJ?
SW626 M1Xwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL3NYxMUUN3ME2yPU44PTZizszN MYfTRW5ITVJ?
LB2518-MEL MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTJ7LkixOUDPxE1? NFTjdGVUSU6JRWK=
RXF393 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrHbIxJUUN3ME2zNE4xQTV{IN88US=> NF35OplUSU6JRWK=
LC4-1 MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC2e3JDUUN3ME2zNE4{ODl{IN88US=> MXXTRW5ITVJ?
NCI-H1694 NHrUemJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT4eGNKSzVyPUOwMlY3OjRizszN Mly2V2FPT0WU
K5 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fJXmlEPTB;M{CuPVcxOiEQvF2= MXLTRW5ITVJ?
HDLM-2 NXPqblU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPRNVdkUUN3ME2zNE46PzJ3IN88US=> M{nFdHNCVkeHUh?=
BCPAP NYDDdYIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTNzLkizO|kh|ryP M{HQN3NCVkeHUh?=
BC-3 M3HNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTN{LkG0NFMh|ryP MojLV2FPT0WU
LB996-RCC M3XzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvxTWM2OD1|Mj6yN|U5KM7:TR?= M175NnNCVkeHUh?=
NCI-H2009 NF3SZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi4eIQ5UUN3ME2zNk41QThzIN88US=> MVHTRW5ITVJ?
HTC-C3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTN|Lke1NVkh|ryP MY\TRW5ITVJ?
LAMA-84 Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;seWUyUUN3ME2zOE41PDB5IN88US=> M{fQWXNCVkeHUh?=
CCRF-CEM M2Dr[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXu5XlBxUUN3ME2zOE42PzF3IN88US=> NGHtemhUSU6JRWK=
AN3-CA NWHGU2I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTN3LkC1Olgh|ryP MUXTRW5ITVJ?
NCI-H1734 NXfCSllCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrwXZJKSzVyPUO1MlI2PjFizszN MkDuV2FPT0WU
Ca-Ski NXzwNYw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\FRVdKSzVyPUO1MlQyODFizszN M{LKWHNCVkeHUh?=
U-266 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTN3Lk[xNVQh|ryP MoryV2FPT0WU
SBC-5 NULuSY82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHH[HFKSzVyPUO1Mlc4QDFizszN MUPTRW5ITVJ?
GT3TKB M3joSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTN5LkGxOUDPxE1? M{HtU3NCVkeHUh?=
MDA-MB-175-VII NE\oPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnEXm52UUN3ME2zO{4zOjR6IN88US=> MVjTRW5ITVJ?
PFSK-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXpTWM2OD1|Nz6yOFM2KM7:TR?= M3HncHNCVkeHUh?=
IMR-5 NX;PT2xZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTN5LkK0PFch|ryP MlHzV2FPT0WU
Daudi MoezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXnTWM2OD1|Nz6zOVk4KM7:TR?= NILmW4FUSU6JRWK=
A498 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXyVlNKSzVyPUO3MlczOThizszN MYfTRW5ITVJ?
SCC-4 M{LE[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv5N5hKSzVyPUO3Mlc5PDNizszN NVXwZoRKW0GQR1XS
COLO-680N Mn3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTN6LkK4PFUh|ryP NVnHXG1LW0GQR1XS
SK-MES-1 NWr3OWRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXFSZpWUUN3ME2zPE4{OjF3IN88US=> NFPadmhUSU6JRWK=
SR M2rHUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGCyeXdKSzVyPUO4MlU1QTVizszN NWPrO3dsW0GQR1XS
LNCaP-Clone-FGC NX7CUnJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjaXGxYUUN3ME2zPE42PjN5IN88US=> M3S4enNCVkeHUh?=
SK-HEP-1 M2PSfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\YPZg3UUN3ME2zPE44QDJ{IN88US=> NVXPXWk4W0GQR1XS
BPH-1 NFXydmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTLTWM2OD1|OD64N|I6KM7:TR?= NFHGVYpUSU6JRWK=
NCI-H1755 NV21N4p2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjDS|ZOUUN3ME2zPU42QDF5IN88US=> MU\TRW5ITVJ?
LXF-289 NGrYXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfGbZdKSzVyPUO5MlgxQDRizszN MnnCV2FPT0WU
SW1088 NV;PV2tGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjq[3dKSzVyPUSwMlIyODdizszN NFLB[3FUSU6JRWK=
MOLT-4 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTRyLkK5NFEh|ryP NXH5XW1LW0GQR1XS
AsPC-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjMNXBKSzVyPUSwMlQ2QDNizszN NHnlcpBUSU6JRWK=
HOP-62 NVvxN4NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTRyLk[1Olgh|ryP M3T1OnNCVkeHUh?=
A172 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTRyLki1NVEh|ryP NHThZpVUSU6JRWK=
SN12C M2q4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTRyLkmzPFUh|ryP MWjTRW5ITVJ?
MDA-MB-231 NXLKd3RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfKTWM2OD12MD65PFk5KM7:TR?= NH;YPJZUSU6JRWK=
RPMI-2650 NWfSfmY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnzbZdKUUN3ME20NU4yPTl|IN88US=> NXuzd3F7W0GQR1XS
KYSE-140 NFvmR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkWxTWM2OD12MT64NVI{KM7:TR?= M4XTZXNCVkeHUh?=
KINGS-1 MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jEZWlEPTB;NEKuOFY6PyEQvF2= NUXGWlljW0GQR1XS
HSC-3 M3y5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\0TXdKSzVyPUSyMlY3PjFizszN M{K4SnNCVkeHUh?=
PC-14 NFHQbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVi3RXdFUUN3ME20N{4yQDh{IN88US=> M1HxdnNCVkeHUh?=
COR-L105 MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTR|Lk[1NFIh|ryP MYnTRW5ITVJ?
BE-13 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTR2LkKzO|Eh|ryP M3XXTXNCVkeHUh?=
NCI-H661 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTR2LkK5OVgh|ryP NES1[plUSU6JRWK=
IST-MEL1 MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfyTnl5UUN3ME20OE4{PTl7IN88US=> MYDTRW5ITVJ?
HCC1806 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTTTWM2OD12ND61PFc{KM7:TR?= NFzrbHNUSU6JRWK=
COLO-800 MmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTR2Lki0OVMh|ryP MYXTRW5ITVJ?
IST-SL2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf0fol7UUN3ME20OU4yOjR5IN88US=> MoXVV2FPT0WU
8305C NVvsZ2dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf3dJA1UUN3ME20OU4{ODlizszN MX;TRW5ITVJ?
UACC-62 Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jXNmlEPTB;NE[uNlg4PSEQvF2= MkfpV2FPT0WU
COR-L23 NF31eGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vIOGlEPTB;NEeuNVk6KM7:TR?= NIDvSHBUSU6JRWK=
EFE-184 NI[wRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH2TWM2OD12Nz6zPFgh|ryP MVzTRW5ITVJ?
DMS-114 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnS2TWM2OD12Nz60NVQ6KM7:TR?= NUDYU4lZW0GQR1XS
KYSE-520 NVjsTllUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TvPWlEPTB;NEiuOVMyPSEQvF2= NXXDWoNuW0GQR1XS
SNG-M M3XGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTR7LkSzOEDPxE1? MoPqV2FPT0WU
A2058 MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LubWlEPTB;NEmuOFg5PSEQvF2= NXr0bmUxW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
+ Expand

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
+ Expand
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development Inc.|Astellas Pharma Inc April 16 2014 Phase 2
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development Inc.|Astellas Pharma Inc April 16 2014 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products4

Tags: buy Linsitinib (OSI-906) | Linsitinib (OSI-906) supplier | purchase Linsitinib (OSI-906) | Linsitinib (OSI-906) cost | Linsitinib (OSI-906) manufacturer | order Linsitinib (OSI-906) | Linsitinib (OSI-906) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID